DATATRAK Signs Its First Imaging CRO Connect Partner, ABX-CRO

CLEVELAND, Oct. 9, 2012 /PRNewswire/ -- DATATRAK International, Inc. (OTCQX: DATA), a leader in developing cloud-based, unified eClinical technologies and delivering related services for the clinical trials industry, today announced a new strategic CRO Connect Partner, ABX-CRO. DATATRAK's CRO Connect Partner Program offers CROs supplemental services with the goal of helping them reduce study costs and further business development objectives.

Based in Dresden, Germany, ABX-CRO provides global molecular and advanced imaging services for oncology and neuroscience to the pharmaceutical and biotechnology industries. ABX-DIRECT, ABX-CRO's HIPAA and 21 CFR Part 11 compliant IT solution for controlled exchange of image data in clinical trials, complements DATATRAK's technologies providing CROs and pharmaceutical companies with full web-based control of virtually any trial data, according to today's traceability and safety standards.

"ABX-CRO is pleased to partner with an EDC pioneer with global reach and outstanding technology for co-marketing of ABX-DIRECT. Using our combined technologies, inclusion and instant expert analysis of advanced imaging endpoints has never been so easy, be it in exploratory development or in late stage multicenter trials," said Dr. Andreas Kluge, Founder and General Manager of ABX-CRO.

"We are thrilled to welcome ABX-CRO to our growing roster of CRO Connect Partner Program clients," commented Dr. Bill Gluck, VP of Clinical & Consulting Services. "Not only does this partnership allow DATATRAK to offer our clients imaging services, ABX-CRO also brings the added value of imaging expertise to our other Connect Partners. DATATRAK continues to build new and innovative partnerships in order to safely accelerate every drug, biologic, and device from Concept to Cure®."


ABX-CRO is an independent full service clinical research organization representing more than 12 years of comprehensive drug development services in nuclear medicine. Key activities include standalone solutions for PET & SPECT imaging in the context of therapeutic trials, advanced Image CoreLab services, as well as integrated development of new PET & SPECT biomarkers.  Customers include both the pharmaceutical and the biotechnology industries. For more information, visit


DATATRAK is the leader of unified eClinical™ technologies and related services for the clinical trials industry.  Using the DATATRAK ONE™ multi-product, cloud-based clinical research platform, DATATRAK's Clinical and Consulting Services™ group assists clients in conducting Phase I-IV drug and device studies in multiple languages throughout the world. DATATRAK has offices located in Cleveland, Ohio; Bryan, Texas; and Cary (RTP), North Carolina. For more information, visit

Except for the historical information contained in this press release, the statements made in this release are forward-looking statements. These forward-looking statements are made based on management's expectations, assumptions, estimates and current beliefs concerning the operations, future results and prospects of the Company and are subject to uncertainties and factors which are difficult to predict and, in many instances, are beyond the control of the Company, and which could cause actual results to differ materially from those contemplated in these forward-looking statements.  For a list of certain factors that may cause actual results to differ materially from those contemplated in these forward looking statements, please see the Company's report filed with the OTCQX Market on August 15, 2012 announcing its results for the three-month period ending June 30, 2012. The Company undertakes no obligation to update publicly or revise any forward-looking statement whether as a result of new information, future events or otherwise.

SOURCE DATATRAK International, Inc.